In 2023, Pfizer solidified its position as a market leader in transthyretin amyloid cardiomyopathy (ATTR-CM) treatment by shipping 2.3 million capsules of tafamidis, sufficient to cover approximately 36,000 patient-years of therapy. To address persistent back-orders in key European and Asian markets, the company’s Freiburg facility brought a second manufacturing line online in February 2024, boosting global supply resilience. This production boost coincided with the rapid expansion of diagnostic imaging: North American and Japanese echocardiography registries identified 11,700 new ATTR-CM cases in 2023, up from roughly 8,500 two years earlier, driving heightened demand for tafamidis. Internal models project that by December 2024, treated patients will grow to 53,000, reflecting both broader technetium-pyrophosphate scan adoption and streamlined distribution channels in emerging markets following recent reimbursement reforms.

Pfizer currently offers investors a dividend yield near 6.7%, one of the highest in its peer group, supported by a forward price-to-earnings ratio of 8.7 versus a five-year peer average of 9.7. While pandemic-related products such as its COVID-19 vaccine and oral antiviral see waning demand, Pfizer is mitigating revenue headwinds through strategic licensing deals and R&D investments. In late 2025, the company struck a collaboration with YaoPharma to co-develop a GLP-1 analog in early clinical stages, targeting the rapidly growing metabolic-disease market in Asia. Concurrently, oncology remains a priority: Pfizer has advanced two novel checkpoint inhibitors into phase 2b studies, with potential launch timelines in 2027, aiming to reclaim growth momentum and sustain its high dividend payout over the long term.